Global Cell Therapy CMO Market Strategic Research Report

Scope of the Report

The global Cell Therapy CMO market size is predicted to grow from US$ 2,827 million in 2025 to US$ 4,617 million in 2032; it is expected to grow at a CAGR of 7.2% from 2026 to 2032.

Cell Therapy CMO is an organization that provides professional, large-scale manufacturing outsourcing services to cell therapy drug development companies. The core of this service lies in helping clients transform their laboratory-scale cell preparation processes into industrial-scale production processes that comply with Good Manufacturing Practices (GMP), solving key challenges in the industrialization of cell therapies, such as process development, quality control, and regulatory compliance. Services cover the entire manufacturing chain of autologous and allogeneic cell therapy products, including viral vector production, cell collection and isolation, gene modification, cell expansion and activation, formulation filling, cryopreservation and transportation, and quality control and release testing. Relying on standardized GMP cleanrooms, closed automated culture systems, and a rigorous quality management system, the CMO ensures the stability, safety, and efficacy of cell products across different batches, thereby accelerating the transition of cell therapy from clinical research to commercial application.

The global Cell Therapy CMO market for cell therapy is experiencing rapid growth driven by the proliferation of cell therapy pipelines and the demand for commercialization. North America and Europe, as mature markets, leverage their leading viral vector technologies, robust GMP systems, and extensive CDMO experience to hold leading positions in the commercial production of autologous CAR-T cells, large-scale lentiviral manufacturing, and closed-loop automated platforms. The Asia-Pacific region has become the fastest-growing and most rapidly expanding sector. China, with its leading global number of cell therapy clinical studies, strong policy support, and cost advantages across the supply chain, is driving the rapid rise of autologous cell therapy CMOs, general-purpose cell manufacturing, and viral vector outsourcing services, with domestic CMOs quickly gaining a competitive edge globally. The industry as a whole is accelerating its evolution towards fully closed-loop automated production, off-the-shelf cell technologies, and a globalized supply chain.

This report presents a comprehensive overview of the global Cell Therapy CMO market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Open-type CMO
• Closed-type CMO

Segment by Cell Source

• Autologous Cell Therapy
• Universal Cell Therapy
• Xenogeneic Cell Therapy

Segment by Cell Types

• Immunotherapy CMO
• Stem Cell Therapy CMO
• Somatic Cell Therapy CMO
• Others

Segment by Application

• Commercial
• Academic Research
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cell Therapy CMO market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Commercial, Academic Research, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact